Otsuka to Launch QuickNaviTM-Noro3, a Norovirus Antigen Quick Detection Kit
27 Sep 2022
Otsuka Pharmaceutical Co., Ltd. will launch the norovirus antigen test kit QuickNavi™- Noro3 to medical institutions across Japan. It is the latest product in the QuickNaviTM series of in vitro diagnostics. The kit, manufactured domestically by Denka Company Limited, will be co-marketed by the two companies from October 26.
QuickNavi™-Noro3 is an assay kit for rapid and specific detection of norovirus antigen in feces using immunochromatography. There are multiple genotypes of norovirus, and compared to QuickNavi™-Noro 2, this product has improved sensitivity for a wide variety of genotypes, including those that have become prevalent in recent years. As with the conventional product, this kit does not require centrifugation or other pretreatment of specimens, and final determination of the presence or absence of the virus can be made within 15 minutes.
Preview
Source: Otsuka
Preview
Source: Otsuka
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.